Investors See Opportunity in Huge Global Demand for Lithium
The global lithium market is projected to surge 500% due to a growing need for lithium-filled batteries. And one junior mining company in a renowned location in South America is in the right place at the right time to capitalize on this megatrend.
Put this company on your investing radar today.

CGTX Insider Trading (Cognition Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $36,000.00
Insider Selling (Last 12 Months): $0.00

Cognition Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cognition Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cognition Therapeutics Share Price & Price History

Current Price: $2.90
Price Change: Price Increase of +0.01 (0.35%)
As of 05/18/2022 01:00 AM ET

This chart shows the closing price history over time for CGTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Copper Exploration Heating Up
Canada is already known as a miner's paradise. But British Columbia (BC) is quietly becoming the new copper hotspot. That's because copper is critical to the world's shift to renewable energy. Biden earmarked $226 billion in new infrastructure projects all requiring copper.
Discover Opportunities in the New Copper Hotspot

Cognition Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/13/2021Peggy WallaceDirectorBuy3,000$12.00$36,000.00View SEC Filing Icon  
See Full Table
The Incredible Dividend Map... Where Stocks Yield 26% a Year!
What’s the highest-yielding stock you’ve ever owned?

The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.

SEC Filings (Institutional Ownership Changes) for Cognition Therapeutics (NASDAQ:CGTX)

23.40% of Cognition Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CGTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Cognition Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/17/2022Worth Venture Partners LLC175,366$0.47M0.2%N/A0.776%Search for SEC Filing on Google Icon
5/17/2022Prosight Management LP240,080$0.66M0.4%-20.5%1.062%Search for SEC Filing on Google Icon
5/13/2022Frontier Wealth Management LLC50,000$0.15M0.0%N/A0.221%Search for SEC Filing on Google Icon
5/13/2022Nantahala Capital Management LLC196,402$0.54M0.0%-6.3%0.869%Search for SEC Filing on Google Icon
5/13/2022Baird Financial Group Inc.20,393$56K0.0%N/A0.090%Search for SEC Filing on Google Icon
5/4/2022Commonwealth Equity Services LLC13,890$38K0.0%N/A0.061%Search for SEC Filing on Google Icon
4/26/2022Diligent Investors LLC30,520$84K0.0%N/A0.135%Search for SEC Filing on Google Icon
4/26/2022Kestra Advisory Services LLC238,666$0.66M0.0%+150.9%1.057%Search for SEC Filing on Google Icon
4/21/2022P.A.W. Capital Corp120,000$0.33M0.3%+20.0%0.531%Search for SEC Filing on Google Icon
4/14/2022Bangor Savings Bank18,496$51K0.0%N/A0.082%Search for SEC Filing on Google Icon
2/23/2022BlackRock Inc.7,997$51K0.0%N/A0.036%Search for SEC Filing on Google Icon
2/15/2022Millennium Management LLC56,419$0.36M0.0%N/A0.256%Search for SEC Filing on Google Icon
2/11/2022Renaissance Technologies LLC11,764$74K0.0%N/A0.053%Search for SEC Filing on Google Icon
2/10/2022B. Riley Financial Inc.30,904$0.20M0.0%N/A0.140%Search for SEC Filing on Google Icon
2/10/2022American Financial Group Inc.205,000$1.30M0.4%N/A0.930%Search for SEC Filing on Google Icon
2/10/2022AIGH Capital Management LLC25,496$0.16M0.0%N/A0.116%Search for SEC Filing on Google Icon
2/10/2022P.A.W. Capital Corp100,000$0.63M0.6%N/A0.454%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cognition Therapeutics logo
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Read More on Cognition Therapeutics

Today's Range

Now: $2.90
Low: $2.68
High: $2.91

50 Day Range

MA: $2.90
Low: $2.41
High: $3.45

52 Week Range

Now: $2.90
Low: $2.31
High: $13.80

Volume

15,428 shs

Average Volume

55,164 shs

Market Capitalization

$65.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Cognition Therapeutics?

Cognition Therapeutics' top insider investors include:
  1. Peggy Wallace (Director)
Learn More about top insider investors at Cognition Therapeutics.

Who are the major institutional investors of Cognition Therapeutics?

Cognition Therapeutics' top institutional shareholders include:
  1. Prosight Management LP — 1.06%
  2. Kestra Advisory Services LLC — 1.06%
  3. Nantahala Capital Management LLC — 0.87%
  4. Worth Venture Partners LLC — 0.78%
  5. P.A.W. Capital Corp — 0.53%
  6. Frontier Wealth Management LLC — 0.22%
Learn More about top institutional investors of Cognition Therapeutics stock.

Which institutional investors are selling Cognition Therapeutics stock?

Within the last quarter, CGTX stock was sold by these institutional investors:
  1. Prosight Management LP
  2. Nantahala Capital Management LLC

Which institutional investors are buying Cognition Therapeutics stock?

During the last quarter, CGTX stock was bought by institutional investors including:
  1. Worth Venture Partners LLC
  2. Kestra Advisory Services LLC
  3. Frontier Wealth Management LLC
  4. Diligent Investors LLC
  5. Baird Financial Group Inc.
  6. P.A.W. Capital Corp
  7. Bangor Savings Bank
  8. Commonwealth Equity Services LLC
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
The US-China "Lithium War" Is Creating Opportunity